ERBB2 and cancer: To validate the potential of EV-based nucleic acid drugs in treating cancer, two drug delivery systems were developed: E7-circp53-EVs for targeting human bone marrow-derived mesenchymal stem cells (hBMMSCs)32 and Her2-circp53-EVs for targeting CRC cells33 (Fig. 6a).